Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

NCT03189914 is registered in ClinicalTrials.gov with Processa Pharmaceuticals as lead sponsor.

NCT NCT03189914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03189914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Lead sponsor
Processa Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
October 2, 2017
Completion date
November 21, 2019
Enrollment
46 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer